Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Yamada T, Goto Y, Tanaka H, Kimura H, Minato K, Gyotoku H, Honda T, Watanabe S, Morimoto K, Kiyomi F, Uchino J, Takayama K. Yamada T, et al. Among authors: goto y. Eur J Cancer. 2023 Dec;195:113373. doi: 10.1016/j.ejca.2023.113373. Epub 2023 Oct 22. Eur J Cancer. 2023. PMID: 37890349 Free article. Clinical Trial.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: goto y. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Takei S, et al. Among authors: goto y. Front Immunol. 2024 Feb 23;15:1348034. doi: 10.3389/fimmu.2024.1348034. eCollection 2024. Front Immunol. 2024. PMID: 38464519 Free PMC article.
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.
Niho S, Goto Y, Toyozawa R, Daga H, Ohashi K, Takahashi T, Tanaka H, Sakakibara-Konishi J, Hattori Y, Morise M, Kodani M, Ikeda T, Izumi H, Matsumoto S, Yoh K, Nomura S, Goto K. Niho S, et al. Among authors: goto y, goto k. ESMO Open. 2024 Aug;9(8):103642. doi: 10.1016/j.esmoop.2024.103642. Epub 2024 Jul 16. ESMO Open. 2024. PMID: 39018589 Free PMC article. Clinical Trial.
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Nishioka N, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Masui T, Sai N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Nishioka N, et al. Among authors: goto y. Front Immunol. 2024 Jul 15;15:1399889. doi: 10.3389/fimmu.2024.1399889. eCollection 2024. Front Immunol. 2024. PMID: 39076994 Free PMC article.
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K. Tachibana Y, et al. Among authors: goto y. Invest New Drugs. 2024 Aug 21. doi: 10.1007/s10637-024-01467-7. Online ahead of print. Invest New Drugs. 2024. PMID: 39168900
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study.
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Nishioka N, et al. Among authors: goto y. Cancer Res Treat. 2024 Oct 25. doi: 10.4143/crt.2024.748. Online ahead of print. Cancer Res Treat. 2024. PMID: 39482992 Free article.
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.
Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. Matsuzawa R, et al. Among authors: goto y. EClinicalMedicine. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38034077 Free PMC article.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: goto y. Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613731 Free PMC article.
4,634 results